词条 | GPNMB |
释义 |
GPNMB is a type I transmembrane glycoprotein which shows homology to the pmel17 precursor, a melanocyte-specific protein. GPNMB has been reported to be expressed in various cell types, including: melanocytes, osteoclasts, osteoblasts, dendritic cells, and it is overexpressed in various cancer types. In melanocytic cells and osteoclasts the GPNMB gene is transcriptionally regulated by Microphthalmia-associated transcription factor.[3][4] FunctionIn osteoblast progenitor cells, Osteoactivin works as a positive regulator of osteoblast differentiation during later stages of matrix maturation and mineralization [5] that is mediated at least in part by BMP-2 in a SMAD1 dependent manner to promote osteoblast differentiation.[6] In addition, using a rat fracture model, Osteoactivin (OA) enhances the repairing process in bone fracture, demonstrated by its high expression during chondrogenesis (soft callus) and osteogenesis (hard callus) compared to the intact femurs [7] that is why Osteoactivin (OA) could be a novel therapeutic agent used to treat generalized osteoporosis or localized osteopenia during fracture repair by stimulating bone growth and regeneration.[8] Similarly, Osteoactivin expression increases during osteoclast differentiation and it is functionally implicated in this process, possibly by promoting the fusion of osteoclast progenitor cells.[9] Clinical and functional significance in cancerGPNMB was originally identified as a gene that was expressed in poorly metastatic human melanoma cell lines and xenografts and not expressed in highly metastatic cell lines. However, several recent studies have identified high GPNMB expression in aggressive melanoma,[10] glioma,[11] and breast cancer specimens.[12] Breast cancerBased on Immunohistochemical analysis, two studies have shown that GPNMB is commonly expressed in breast tumors. In the first study, GPNMB was detected in 71% (10/14) of breast tumors.[13] In the second study, 64% of human breast tumors express GPNMB in the tumor stroma and an additional 10% of tumors express GPNMB in the tumor epithelium.[14] In this study it was reported that GPNMB expression in the tumor epithelium was an independent prognostic indicator of breast cancer recurrence. Moreover, epithelial GPNMB expression was most abundant in triple negative breast cancers and it was found to be a prognostic marker for shorter metastasis-free survival times within this breast cancer subtype. Finally, GPNMB expression in breast cancer cells is capable of promoting cell migration, invasion, and metastasis both in vitro and in vivo.[12][14] GPNMB as a target for therapyGPNMB is the target of the antibody glembatumumab (CR011) which is used in the antibody-drug conjugate glembatumumab vedotin (CDX-011, CR011-vcMMAE)[15] which is in clinical trials for melanoma and breast cancer. (See glembatumumab vedotin) References1. ^{{cite journal | vauthors = Weterman MA, Ajubi N, van Dinter IM, Degen WG, van Muijen GN, Ruitter DJ, Bloemers HP | title = nmb, a novel gene, is expressed in low-metastatic human melanoma cell lines and xenografts | journal = International Journal of Cancer | volume = 60 | issue = 1 | pages = 73–81 | date = January 1995 | pmid = 7814155 | doi = 10.1002/ijc.2910600111 | hdl = 2066/20693 }} 2. ^1 {{cite web | title = Entrez Gene: GPNMB glycoprotein (transmembrane) nmb| url = https://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=10457| accessdate = }} 3. ^{{cite journal | vauthors = Loftus SK, Antonellis A, Matera I, Renaud G, Baxter LL, Reid D, Wolfsberg TG, Chen Y, Wang C, Prasad MK, Bessling SL, McCallion AS, Green ED, Bennett DC, Pavan WJ | title = Gpnmb is a Melanoblast-Expressed, MITF-Dependent Gene | journal = Pigment Cell & Melanoma Research | volume = 22 | issue = 1 | pages = 99–110 | date = February 2009 | pmid = 18983539 | pmc = 2714741 | doi = 10.1111/j.1755-148X.2008.00518.x }} 4. ^{{cite journal | vauthors = Hoek KS, Schlegel NC, Eichhoff OM, Widmer DS, Praetorius C, Einarsson SO, Valgeirsdottir S, Bergsteinsdottir K, Schepsky A, Dummer R, Steingrimsson E | title = Novel MITF targets identified using a two-step DNA microarray strategy | journal = Pigment Cell & Melanoma Research | volume = 21 | issue = 6 | pages = 665–76 | date = December 2008 | pmid = 19067971 | doi = 10.1111/j.1755-148X.2008.00505.x }} 5. ^{{cite journal | vauthors = Abdelmagid SM, Barbe MF, Rico MC, Salihoglu S, Arango-Hisijara I, Selim AH, Anderson MG, Owen TA, Popoff SN, Safadi FF | title = Osteoactivin, an anabolic factor that regulates osteoblast differentiation and function | journal = Exp Cell Res | volume = 314 | issue = 13 | pages = 2334–51 | date = 1 August 2008 | pmid = 18555216 | doi = 10.1016/j.yexcr.2008.02.006 }} 6. ^{{cite journal | vauthors = Abdelmagid SM, Barbe MF, Arango-Hisijara I, Owen TA, Popoff SN, Safadi FF | title = Osteoactivin acts as downstream mediator of BMP-2 effects on osteoblast function | journal = J. Cell. Physiol. | volume = 210 | issue = 1 | pages = 26–37 | year = 2007 | pmid = 17034042 | doi = 10.1002/jcp.20841}} 7. ^{{cite journal | vauthors = Abdelmagid SM, Barbe MF, Hadjiargyrou M, Owen TA, Razmpour R, Rehman S, Popoff SN, Safadi FF | title = Temporal and spatial expression of osteoactivin during fracture repair | journal = J Cell Biochem | volume = 111 | issue = 2 | pages = 295–309 | date = 1 Oct 2010 | pmid = 20506259 | doi = 10.1002/jcb.22702 }} 8. ^{{cite book|last=Abdelmagid|first=Samir|title=Role of Osteoactivin in Bone Formation and Fracture Repair|year=2010|publisher=LAP Lambert Academic Publishing|location=USA|isbn=978-3-8383-5436-1|pages=144}} 9. ^{{cite journal | vauthors = Sheng MH, Wergedal JE, Mohan S, Lau KH | title = Osteoactivin is a novel osteoclastic protein and plays a key role in osteoclast differentiation and activity | journal = FEBS Lett. | volume = 582 | issue = 10 | pages = 1451–8 | date = October 2008 | pmid = 18381073 | doi = 10.1016/j.febslet.2008.03.030}} 10. ^{{cite journal | vauthors = Tse KF, Jeffers M, Pollack VA, McCabe DA, Shadish ML, Khramtsov NV, Hackett CS, Shenoy SG, Kuang B, Boldog FL, MacDougall JR, Rastelli L, Herrmann J, Gallo M, Gazit-Bornstein G, Senter PD, Meyer DL, Lichenstein HS, LaRochelle WJ | title = CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma | journal = Clinical Cancer Research | volume = 12 | issue = 4 | pages = 1373–82 | date = February 2006 | pmid = 16489096 | doi = 10.1158/1078-0432.CCR-05-2018 }} 11. ^{{cite journal | vauthors = Kuan CT, Wakiya K, Dowell JM, Herndon JE, Reardon DA, Graner MW, Riggins GJ, Wikstrand CJ, Bigner DD | title = Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme | journal = Clinical Cancer Research | volume = 12 | issue = 7 Pt 1 | pages = 1970–82 | date = April 2006 | pmid = 16609006 | doi = 10.1158/1078-0432.CCR-05-2797 }} 12. ^1 {{cite journal | vauthors = Rose AA, Pepin F, Russo C, Abou Khalil JE, Hallett M, Siegel PM | title = Osteoactivin promotes breast cancer metastasis to bone | journal = Molecular Cancer Research | volume = 5 | issue = 10 | pages = 1001–14 | date = October 2007 | pmid = 17951401 | doi = 10.1158/1541-7786.MCR-07-0119}} 13. ^{{cite journal|vauthors=Burris H, Saleh M, Bendell J, Hart L, Rose A, Dong Z, Siegel P, Crane M, Donovan D, Crowley D, Simantov R, Vahdat L |title=A Phase (Ph) I/II Study of CR011-VcMMAE, an Antibody-Drug Conjugate, in Patients (Pts) with Locally Advanced or Metastatic Breast Cancer (MBC) |journal=Cancer Research |date=December 2009 |volume=69 |issue=24 (Meeting Abstract Supplement) |pages=6096 |doi=10.1158/0008-5472.SABCS-09-6096 |url=http://cancerres.aacrjournals.org/cgi/content/abstract/69/24_MeetingAbstracts/6096?sid=86581d39-486c-4dc5-95b3-63454efd0cec }}{{dead link|date=January 2017 |bot=InternetArchiveBot |fix-attempted=yes }} 14. ^1 {{cite journal | vauthors = Rose AA, Grosset AA, Dong Z, Russo C, Macdonald PA, Bertos NR, St-Pierre Y, Simantov R, Hallett M, Park M, Gaboury L, Siegel PM | title = Glycoprotein Nonmetastatic B Is an Independent Prognostic Indicator of Recurrence and a Novel Therapeutic Target in Breast Cancer | journal = Clinical Cancer Research | volume = 16 | issue = 7 | pages = 2147–2156 | date = April 2010 | pmid = 20215530 | doi = 10.1158/1078-0432.CCR-09-1611 }} 15. ^NCI Drug Dictionary: Glemtumumab vedotin Further reading{{refbegin | 2}}
|
随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识,基本涵盖了大多数领域的百科知识,是一部内容自由、开放的电子版国际百科全书。